Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Kodiak Sciences Inc Market Cap
Based on ratings from 8 stock analysts, the Kodiak Sciences Inc stock price is expected to decrease by 33.33% in 12 months. This is calculated by using the average 12-month stock price forecast for Kodiak Sciences Inc. The lowest target is $2 and the highest is $20. Please note analyst price targets are not guaranteed and could be missed completely.
KOD is a stock in Healthcare which has been forecasted to be worth $6.66667 as an average. On the higher end, the forecast price is $20 USD by Michael Yee from Jefferies and on the lower end KOD is forecasted to be $2 by Gena Wang from Barclays.
These are the latest 20 analyst ratings of KOD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Yee Jefferies | Buy | $20 | Upgrade | Dec 9, 2024 |
| Matthew Caufield HC Wainwright & Co. | Neutral | $3 | Reiterates | Nov 15, 2024 |
| Gena Wang Barclays | Underweight | $4 | Maintains | Nov 15, 2024 |
| Matthew Caufield HC Wainwright & Co. | Neutral | $3 | Reiterates | Sep 24, 2024 |
| Matthew Caufield HC Wainwright & Co. | Neutral | $3 | Initiates | Sep 5, 2024 |
| Eliana Merle UBS | Neutral | $5 | Maintains | Apr 4, 2024 |
| Gena Wang Barclays | Underweight | $3 | Maintains | Apr 1, 2024 |
| Eliana Merle UBS | Neutral | $3 | Maintains | Dec 21, 2023 |
| Andrea Tan Goldman Sachs | Sell | $2 | Reinstates | Dec 11, 2023 |
| Zegbeh Jallah Capital One | Overweight | Upgrade | Nov 17, 2023 | |
| Eliana Merle UBS | Neutral | $4 | Downgrade | Jul 27, 2023 |
| Daniil Gataulin Chardan Capital | Neutral | Downgrade | Jul 25, 2023 | |
| Anupam Rama JP Morgan | Underweight | Downgrade | Jul 25, 2023 | |
| Gena Wang Barclays | Underweight | $2 | Maintains | Jul 25, 2023 |
| Michael Yee Jefferies | Hold | $3 | Downgrade | Jul 24, 2023 |
| Zegbeh Jallah Capital One | Equal-Weight | $7 | Downgrade | Jul 24, 2023 |
| Anupam Rama JP Morgan | Neutral | $10 | Maintains | Apr 4, 2023 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $9 | Maintains | Nov 14, 2022 |
| Graig Suvannavejh Goldman Sachs | Neutral | $8 | Maintains | Nov 10, 2022 |
| Matthew Harrison Morgan Stanley | Equal-Weight | $12 | Maintains | Aug 15, 2022 |
When did it IPO
2018
Staff Count
111
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Victor Perlroth M.D.
Market Cap
$526.2M
In 2023, KOD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KOD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Jefferies has upgraded Kodiak Sciences Inc. (KOD), a biopharmaceutical company specializing in treatments for retinal diseases.
Why It Matters - Jefferies' upgrade of Kodiak Sciences indicates increased confidence in the company's potential for growth, potentially driving stock prices up and attracting more investor interest.
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Kodiak Sciences Inc. (KOD) has reached a key support level, and its 50-day moving average has crossed above the 200-day moving average, indicating a potential bullish trend.
Why It Matters - Kodiak Sciences' golden cross suggests positive momentum and potential bullish trends, indicating a favorable entry point for traders and enhancing investor sentiment.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Kodiak Sciences Inc. (Nasdaq: KOD) released its business highlights and financial results for Q3 2024 on November 14, 2024.
Why It Matters - Kodiak Sciences' quarterly financial results can impact stock performance, investor sentiment, and future growth potential, influencing investment decisions in the biotech sector.
Fri, 15 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - KOD reported a narrower-than-expected loss for Q3 2024 and provided updates on its pipeline development plans.
Why It Matters - KOD's narrower loss indicates improved financial health, potentially boosting investor confidence, while pipeline updates may signal future growth opportunities.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Kodiak Sciences Inc. (Nasdaq: KOD) will present at upcoming investor conferences, focusing on its research and development in retinal disease therapeutics.
Why It Matters - Kodiak Sciences' participation in investor conferences indicates potential for increased visibility and interest in its developments, which can influence stock performance and investor sentiment.
Mon, 14 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Kodiak Sciences Inc. (Nasdaq: KOD) will participate in a presentation and panel at Innovate Retina 2024 on October 17 in Chicago, focusing on retinal disease therapeutics.
Why It Matters - Kodiak Sciences' participation in Innovate Retina 2024 highlights its commitment to innovation in retinal disease therapies, potentially attracting investor interest and impacting stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
